Skip to main content
Top
Published in: Endocrine 2/2017

Open Access 01-11-2017 | Original Article

Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms

Authors: Emanuele Leoncini, Paolo Boffetta, Michail Shafir, Katina Aleksovska, Stefania Boccia, Guido Rindi

Published in: Endocrine | Issue 2/2017

Login to get access

Abstract

Purpose

The incidence of neuroendocrine neoplasms is increasing. This work aimed at: (i) establishing worldwide incidence trend of low-grade neuroendocrine neoplasms; (ii) defining the incidence and temporal trend of high-grade neuroendocrine neoplasms in USA utilizing the Surveillance Epidemiology and End Results database; (iii) comparing trends for low-grade vs. high-grade neuroendocrine neoplasms.

Methods

We conducted a literature search on MEDLINE and Scopus databases and incidence trends were plotted for 1973-2012. The Surveillance Epidemiology and End Results database was used to identify incidence rates in USA for 1973-2012. Incidence rates were stratified according to histological grade, gender and ethnicity. Trends were summarized as annual percent change and corresponding 95% confidence interval.

Results

11 studies were identified involving 72,048 cases; neuroendocrine neoplasm incidence rates increased over time in all countries for all sites, except for appendix. In Surveillance Epidemiology and End Results low-grade neuroendocrine neoplasm incidence rate increased from 1.09 in 1973 to 3.51 per 100,000 in 2012. During this interval, high-grade neuroendocrine neoplasm incidence rate increased from 2.54 to 10.52 per 100,000. African Americans had the highest rates of digestive neuroendocrine neoplasms with male prevalence in high-grade.

Conclusions

Our data indicate an increase in the incidence of neuroendocrine neoplasms as a worldwide phenomenon, affecting most anatomical sites and involving both low-grade and high-grade neoplasms.
Appendix
Available only for authorised users
Literature
1.
go back to reference F. Inzani, G. Rindi. Classification of Neuroendocrine Neoplasms. in Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. Contemporary Endocrinology. ed. by K. Pacak, D. Taïeb (Springer, Cham, 2017), pp. 1–14 F. Inzani, G. Rindi. Classification of Neuroendocrine Neoplasms. in Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. Contemporary Endocrinology. ed. by K. Pacak, D. Taïeb (Springer, Cham, 2017), pp. 1–14
2.
go back to reference G. Rindi, R. Arnold, C. Capella, D.S. Klimstra, G. Klöppel, P. Komminoth, E. Solcia. Nomenclature and classification of digestive neuroendocrine tumours. in World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System. ed.by F. Bosman, F. Carneiro (IARC, Lyon, 2010) pp. 10–12 G. Rindi, R. Arnold, C. Capella, D.S. Klimstra, G. Klöppel, P. Komminoth, E. Solcia. Nomenclature and classification of digestive neuroendocrine tumours. in World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System. ed.by F. Bosman, F. Carneiro (IARC, Lyon, 2010) pp. 10–12
3.
go back to reference M. Milione, P. Maisonneuve, F. Spada, A. Pellegrinelli, P. Spaggiari, L. Albarello, E. Pisa, M. Barberis, A. Vanoli, R. Buzzoni, S. Pusceddu, L. Concas, F. Sessa, E. Solcia, C. Capella, N. Fazio, S. La Rosa, The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104(1), 85–93 (2017). doi:10.1159/000445165 CrossRefPubMed M. Milione, P. Maisonneuve, F. Spada, A. Pellegrinelli, P. Spaggiari, L. Albarello, E. Pisa, M. Barberis, A. Vanoli, R. Buzzoni, S. Pusceddu, L. Concas, F. Sessa, E. Solcia, C. Capella, N. Fazio, S. La Rosa, The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104(1), 85–93 (2017). doi:10.​1159/​000445165 CrossRefPubMed
4.
go back to reference M.B. Amin, S.B. Edge, F.L. Greene, D.R. Byrd, D.B. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer (eds.), AJCC Cancer Staging. Manual, 8th ed. (Springer, New York, Philadelphia, 2017) M.B. Amin, S.B. Edge, F.L. Greene, D.R. Byrd, D.B. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer (eds.), AJCC Cancer Staging. Manual, 8th ed. (Springer, New York, Philadelphia, 2017)
5.
go back to reference E.A. Woltering, E.K. Bergsland, D.T. Beyer, T.M. O’Dorisio, G. Rindi, D.S. Klimstra, L.H. Tang, D. Reidy-Lagunes, J.R. Strosberg, E.M. Wolin, A.I. Vinik, E.K. Nakakura, E.A. Asare, D.L. Bushnell, R.L. Schilsky, Y.-Z. Wang, M.K. Kim, E.H. Liu, R.T. Jensen, R.K.S. Wong, J.K. Ramage, K. Mallin, R.F. Pommier: Neuroendocrine tumors of the jejunum and ileum. In: M.B. Amin, S.B. Edge, F.L. Greene, D.R. Byrd, D.B. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer (eds.) AJCC Cancer Staging Manual. (Springer, New York, Philadelphia, 2017), pp. 375–387 E.A. Woltering, E.K. Bergsland, D.T. Beyer, T.M. O’Dorisio, G. Rindi, D.S. Klimstra, L.H. Tang, D. Reidy-Lagunes, J.R. Strosberg, E.M. Wolin, A.I. Vinik, E.K. Nakakura, E.A. Asare, D.L. Bushnell, R.L. Schilsky, Y.-Z. Wang, M.K. Kim, E.H. Liu, R.T. Jensen, R.K.S. Wong, J.K. Ramage, K. Mallin, R.F. Pommier: Neuroendocrine tumors of the jejunum and ileum. In: M.B. Amin, S.B. Edge, F.L. Greene, D.R. Byrd, D.B. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer (eds.) AJCC Cancer Staging Manual. (Springer, New York, Philadelphia, 2017), pp. 375–387
8.
go back to reference C. Lepage, A.M. Bouvier, S. Manfredi, V. Dancourt, J. Faivre, Incidence and management of primary malignant small bowel cancers: a well-defined French population study. The American journal of gastroenterology 101(12), 2826–2832 (2006). doi:10.1111/j.1572-0241.2006.00854.x C. Lepage, A.M. Bouvier, S. Manfredi, V. Dancourt, J. Faivre, Incidence and management of primary malignant small bowel cancers: a well-defined French population study. The American journal of gastroenterology 101(12), 2826–2832 (2006). doi:10.​1111/​j.​1572-0241.​2006.​00854.​x
9.
go back to reference O. Hauso, B.I. Gustafsson, M. Kidd, H.L. Waldum, I. Drozdov, A.K. Chan, I.M. Modlin, Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113(10), 2655–2664 (2008). doi:10.1002/cncr.23883 CrossRefPubMed O. Hauso, B.I. Gustafsson, M. Kidd, H.L. Waldum, I. Drozdov, A.K. Chan, I.M. Modlin, Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113(10), 2655–2664 (2008). doi:10.​1002/​cncr.​23883 CrossRefPubMed
12.
14.
go back to reference C.M. Korse, B.G. Taal, M.L. van Velthuysen, O. Visser, Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. European journal of cancer 49(8), 1975–1983 (2013). doi:10.1016/j.ejca.2012.12.022 C.M. Korse, B.G. Taal, M.L. van Velthuysen, O. Visser, Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. European journal of cancer 49(8), 1975–1983 (2013). doi:10.​1016/​j.​ejca.​2012.​12.​022
15.
go back to reference H. Scherubl, B. Streller, R. Stabenow, H. Herbst, M. Hopfner, C. Schwertner, J. Steinberg, J. Eick, W. Ring, K. Tiwari, S.M. Zappe, Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J. Gastroenterol. 19(47), 9012–9019 (2013). doi:10.3748/wjg.v19.i47.9012 CrossRefPubMedPubMedCentral H. Scherubl, B. Streller, R. Stabenow, H. Herbst, M. Hopfner, C. Schwertner, J. Steinberg, J. Eick, W. Ring, K. Tiwari, S.M. Zappe, Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J. Gastroenterol. 19(47), 9012–9019 (2013). doi:10.​3748/​wjg.​v19.​i47.​9012 CrossRefPubMedPubMedCentral
16.
go back to reference J. Hallet, C.H. Law, M. Cukier, R. Saskin, N. Liu, S. Singh, Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121(4), 589–597 (2015). doi:10.1002/cncr.29099 CrossRefPubMed J. Hallet, C.H. Law, M. Cukier, R. Saskin, N. Liu, S. Singh, Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121(4), 589–597 (2015). doi:10.​1002/​cncr.​29099 CrossRefPubMed
17.
go back to reference J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J.E. Mares, E.K. Abdalla, J.B. Fleming, J.N. Vauthey, A. Rashid, D.B. Evans, One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063–3072 (2008). doi:10.1200/JCO.2007.15.4377 CrossRefPubMed J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J.E. Mares, E.K. Abdalla, J.B. Fleming, J.N. Vauthey, A. Rashid, D.B. Evans, One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063–3072 (2008). doi:10.​1200/​JCO.​2007.​15.​4377 CrossRefPubMed
18.
go back to reference O.M. Sandvik, K. Soreide, E. Gudlaugsson, J.T. Kvaloy, J.A. Soreide, Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. Br. J. Surg. 103(3), 226–232 (2016). doi:10.1002/bjs.10034 CrossRefPubMed O.M. Sandvik, K. Soreide, E. Gudlaugsson, J.T. Kvaloy, J.A. Soreide, Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. Br. J. Surg. 103(3), 226–232 (2016). doi:10.​1002/​bjs.​10034 CrossRefPubMed
19.
go back to reference R. Boyar Cetinkaya, B. Aagnes, E. Thiis-Evensen, S. Tretli, D.S. Bergestuen, S. Hansen, Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology 104(1), 1–10 (2017). doi:10.1159/000442207 CrossRefPubMed R. Boyar Cetinkaya, B. Aagnes, E. Thiis-Evensen, S. Tretli, D.S. Bergestuen, S. Hansen, Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology 104(1), 1–10 (2017). doi:10.​1159/​000442207 CrossRefPubMed
20.
go back to reference D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br. Med. J. 339, b2535 (2009). doi:10.1136/bmj.b2535 CrossRef D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br. Med. J. 339, b2535 (2009). doi:10.​1136/​bmj.​b2535 CrossRef
22.
go back to reference H.J. Kim, M.P. Fay, E.J. Feuer, D.N. Midthune, Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19(3), 335–351 (2000). doi:10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-ZCrossRefPubMed H.J. Kim, M.P. Fay, E.J. Feuer, D.N. Midthune, Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19(3), 335–351 (2000). doi:10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-ZCrossRefPubMed
23.
go back to reference F.L. Velayoudom-Cephise, P. Duvillard, L. Foucan, J. Hadoux, C.N. Chougnet, S. Leboulleux, D. Malka, J. Guigay, D. Goere, T. Debaere, C. Caramella, M. Schlumberger, D. Planchard, D. Elias, M. Ducreux, J.Y. Scoazec, E. Baudin, Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr. Relat. Cancer 20(5), 649–657 (2013). doi:10.1530/ERC-13-0027 CrossRefPubMed F.L. Velayoudom-Cephise, P. Duvillard, L. Foucan, J. Hadoux, C.N. Chougnet, S. Leboulleux, D. Malka, J. Guigay, D. Goere, T. Debaere, C. Caramella, M. Schlumberger, D. Planchard, D. Elias, M. Ducreux, J.Y. Scoazec, E. Baudin, Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr. Relat. Cancer 20(5), 649–657 (2013). doi:10.​1530/​ERC-13-0027 CrossRefPubMed
24.
go back to reference H. Sorbye, S. Welin, S.W. Langer, L.W. Vestermark, N. Holt, P. Osterlund, S. Dueland, E. Hofsli, M.G. Guren, K. Ohrling, E. Birkemeyer, E. Thiis-Evensen, M. Biagini, H. Gronbaek, L.M. Soveri, I.H. Olsen, B. Federspiel, J. Assmus, E.T. Janson, U. Knigge: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann. Oncol. (2012). doi:10.1093/annonc/mds276 H. Sorbye, S. Welin, S.W. Langer, L.W. Vestermark, N. Holt, P. Osterlund, S. Dueland, E. Hofsli, M.G. Guren, K. Ohrling, E. Birkemeyer, E. Thiis-Evensen, M. Biagini, H. Gronbaek, L.M. Soveri, I.H. Olsen, B. Federspiel, J. Assmus, E.T. Janson, U. Knigge: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann. Oncol. (2012). doi:10.​1093/​annonc/​mds276
25.
go back to reference M. Heetfeld, C.N. Chougnet, I.H. Olsen, A. Rinke, I. Borbath, G. Crespo, J. Barriuso, M. Pavel, D. O’Toole, T. Walter; other Knowledge Network, m. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr. Relat. Cancer 22(4), 657–664 (2015). doi:10.1530/ERC-15-0119 CrossRefPubMed M. Heetfeld, C.N. Chougnet, I.H. Olsen, A. Rinke, I. Borbath, G. Crespo, J. Barriuso, M. Pavel, D. O’Toole, T. Walter; other Knowledge Network, m. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr. Relat. Cancer 22(4), 657–664 (2015). doi:10.​1530/​ERC-15-0119 CrossRefPubMed
26.
go back to reference O. Basturk, Z. Yang, L.H. Tang, R.H. Hruban, V. Adsay, C.M. McCall, A.M. Krasinskas, K.T. Jang, W.L. Frankel, S. Balci, C. Sigel, D.S. Klimstra, The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am. J. Surg. Pathol. 39(5), 683–690 (2015). doi:10.1097/PAS.0000000000000408 CrossRefPubMedPubMedCentral O. Basturk, Z. Yang, L.H. Tang, R.H. Hruban, V. Adsay, C.M. McCall, A.M. Krasinskas, K.T. Jang, W.L. Frankel, S. Balci, C. Sigel, D.S. Klimstra, The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am. J. Surg. Pathol. 39(5), 683–690 (2015). doi:10.​1097/​PAS.​0000000000000408​ CrossRefPubMedPubMedCentral
28.
29.
go back to reference C.S. Jianu, R. Fossmark, T. Viset, G. Qvigstad, O. Sordal, R. Marvik, H.L. Waldum, Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment. Pharmacol. Ther. 36(7), 644–649 (2012). doi:10.1111/apt.12012 CrossRefPubMed C.S. Jianu, R. Fossmark, T. Viset, G. Qvigstad, O. Sordal, R. Marvik, H.L. Waldum, Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment. Pharmacol. Ther. 36(7), 644–649 (2012). doi:10.​1111/​apt.​12012 CrossRefPubMed
31.
go back to reference Prevention, C.f.D.C.a.: Current Cigarette Smoking Among Adults–United States, in Morbidity and Mortality Weekly Report, 2005–2014, Vol. 64. (Prevention C.f.D.C.a. Washington, DC, 2015), pp. 1233–1240 Prevention, C.f.D.C.a.: Current Cigarette Smoking Among Adults–United States, in Morbidity and Mortality Weekly Report, 2005–2014, Vol. 64. (Prevention C.f.D.C.a. Washington, DC, 2015), pp. 1233–1240
33.
go back to reference M. Hashibe, P. Brennan, S. Benhamou, X. Castellsague, C. Chen, M.P. Curado, L. Dal Maso, A.W. Daudt, E. Fabianova, L. Fernandez, V. Wunsch-Filho, S. Franceschi, R.B. Hayes, R. Herrero, S. Koifman, C. La Vecchia, P. Lazarus, F. Levi, D. Mates, E. Matos, A. Menezes, J. Muscat, J. Eluf-Neto, A.F. Olshan, P. Rudnai, S.M. Schwartz, E. Smith, E.M. Sturgis, N. Szeszenia-Dabrowska, R. Talamini, Q. Wei, D.M. Winn, D. Zaridze, W. Zatonski, Z.F. Zhang, J. Berthiller, P. Boffetta, Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J. Natl. Cancer Inst. 99(10), 777–789 (2007). doi:10.1093/jnci/djk179 CrossRefPubMed M. Hashibe, P. Brennan, S. Benhamou, X. Castellsague, C. Chen, M.P. Curado, L. Dal Maso, A.W. Daudt, E. Fabianova, L. Fernandez, V. Wunsch-Filho, S. Franceschi, R.B. Hayes, R. Herrero, S. Koifman, C. La Vecchia, P. Lazarus, F. Levi, D. Mates, E. Matos, A. Menezes, J. Muscat, J. Eluf-Neto, A.F. Olshan, P. Rudnai, S.M. Schwartz, E. Smith, E.M. Sturgis, N. Szeszenia-Dabrowska, R. Talamini, Q. Wei, D.M. Winn, D. Zaridze, W. Zatonski, Z.F. Zhang, J. Berthiller, P. Boffetta, Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J. Natl. Cancer Inst. 99(10), 777–789 (2007). doi:10.​1093/​jnci/​djk179 CrossRefPubMed
35.
go back to reference E.E. Ilett, S.W. Langer, I.H. Olsen, B. Federspiel, A. Kjaer, U. Knigge, Neuroendocrine carcinomas of the gastroenteropancreatic system: a comprehensive review. Diagnostics (Basel) 5(2), 119–176 (2015). doi:10.3390/diagnostics5020119 CrossRef E.E. Ilett, S.W. Langer, I.H. Olsen, B. Federspiel, A. Kjaer, U. Knigge, Neuroendocrine carcinomas of the gastroenteropancreatic system: a comprehensive review. Diagnostics (Basel) 5(2), 119–176 (2015). doi:10.​3390/​diagnostics50201​19 CrossRef
36.
go back to reference European parliament and council of the European communities. Decision no. 1295/1999/EC of the European parliament and of the council of 29 April 1999 adopting a programme of community action on rare diseases within the framework for action in the field of public health (1999–2003). (1999) European parliament and council of the European communities. Decision no. 1295/1999/EC of the European parliament and of the council of 29 April 1999 adopting a programme of community action on rare diseases within the framework for action in the field of public health (1999–2003). (1999)
37.
go back to reference National Institutes of Health, Annual report on the rare diseases research activities at the National Institutes of Health, FY in 2005 (National Institutes of Health, Bethesda, MD, 2006) National Institutes of Health, Annual report on the rare diseases research activities at the National Institutes of Health, FY in 2005 (National Institutes of Health, Bethesda, MD, 2006)
38.
go back to reference National Cancer Institute Epidemiology and Genetics Research, Synergizing epidemiologic research on rare cancers. Workshop, May 10-11 2007, Bethesda, MD. National Cancer Institute Epidemiology and Genetics Research, Synergizing epidemiologic research on rare cancers. Workshop, May 10-11 2007, Bethesda, MD.
Metadata
Title
Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms
Authors
Emanuele Leoncini
Paolo Boffetta
Michail Shafir
Katina Aleksovska
Stefania Boccia
Guido Rindi
Publication date
01-11-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1273-x

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.